Global Cancer Diagnostics Partnering 2014-2019: Deal Trends, Players and Financials

This report provides details of the latest Cancer Diagnostics agreements announced in the life sciences since 2014.

The report takes the reader through a comprehensive review Cancer Diagnostics deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Cancer Diagnostics partnering deals.

The report presents financial deal term values for Cancer Diagnostics deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Cancer Diagnostics partnering field; both the leading deal values and most active Cancer Diagnostics dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 650 online deal records of actual Cancer Diagnostics deals, as disclosed by the deal parties, are included towards the end of the report in a directory format – by company A-Z, stage of development, deal type, therapy focus, and technology type – that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Cancer Diagnostics dealmaking.

• Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Cancer Diagnostics dealmaking since 2014, including details of headline, upfront, milestone and royalty terms.
• Chapter 3 provides a review of the leading Cancer Diagnostics deals since 2014. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
• Chapter 4 provides a comprehensive listing of the top 25 most active companies in Cancer Diagnostics dealmaking with a brief summary followed by a comprehensive listing of Cancer Diagnostics deals announced by that company, as well as contract documents, where available.
• Chapter 5 provides a comprehensive and detailed review of Cancer Diagnostics partnering deals signed and announced since Jan 2014, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.
• Chapter 6 provides a comprehensive and detailed review of Cancer Diagnostics partnering deals signed and announced since Jan 2014. The chapter is organized by specific Cancer Diagnostics technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

Key benefits

• In-depth understanding of Cancer Diagnostics deal trends since 2014
• Access to headline, upfront, milestone and royalty data
• Analysis of the structure of Cancer Diagnostics agreements with numerous real life case studies
• Detailed access to actual Cancer Diagnostics contracts entered into by leading biopharma companies
• Identify most active Cancer Diagnostics dealmakers since 2014
• Insight into terms included in a Cancer Diagnostics partnering agreement, with real world examples
• Understand the key deal terms companies have agreed in previous deals
• Undertake due diligence to assess suitability of your proposed deal terms for partner companies

In Global Cancer Diagnostics Partnering 2014-2019: Deal trends, players, financials and forecasts, the available deals are listed by:

• Company A-Z
• Headline value
• Stage of development at signing
• Deal component type
• Specific therapy target
• Technology type

Analyzing actual contract agreements allows assessment of the following:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

– Business Wire